Research
Reorienting Health Aid to Meet Post-2015 Global Health Challenges: A Case Study of Sweden as a Donor
Screening Mammography for Free: Impact of Eliminating Cost Sharing on Cancer Screening Rates
The Introduction of Generic Risperidone in Medicare Part D
The introduction of generic second-generation anti-psychotics (SGAs), starting with risperidone in July 2008, could reduce antipsychotic spending and cost-related use barriers.
Use of Second-Generation Antipsychotics and the Introduction of Generic Risperidone in Medicare Part D
Competition and Biosimilar Products--In Reply
Drs Frankel and McKay first note that the FDA is able to ensure biosimilar and reference biologic quality through prerelease specifications.
How Much Donor Financing for Health is Channeled to Global Versus Country-Specific Aid Functions?
The slow global response to the Ebola crisis in west Africa suggests that important gaps exist in donor financing for key global functions, such as support for health research and development for dise
Patents, Monopoly Power, and the Pricing of Pharmaceuticals in Low-income Nations
Research: Perhaps Market Forces Do Work in Health Care After All
Economists’ Declaration on Universal Health Coverage
The author offers insights on a sustainable development agenda launched by the United Nations to call on global policy makers to prioritize a pro-poor pathway to universal health coverage as an essent
Get smart & reliable public policy insights right in your inbox.